ArticleScience advances2020
Identification of human CD4
Abstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Cytotoxic CD4Parasite immunology · 2026Article
- Pharmacologic DPP-4 inhibition promotes CD8bioRxiv : the preprint server for biology · 2026Article
- Th17-driven CD8Cell death & disease · 2026Article
- Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors.Biomarker research · 2026Review
- Review
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.Immunotherapy · 2025Article
- Deconvoluting TCR-dependent and -independent activation is vital for reliable Ag-specific CD4Science advances · 2025Article
- Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4Frontiers in immunology · 2025Article
- In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy.Journal of hematology & oncology · 2024Review
- ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis.Journal for immunotherapy of cancer · 2024Article
- Review
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy.Cancers · 2024Review
- Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2024Article
- The role of CD4Translational cancer research · 2024Article
- CTLs heterogeneity and plasticity: implications for cancer immunotherapy.Molecular cancer · 2024Review
- Altered IL-7 signaling in CD4+ T cells from patients with visceral leishmaniasis.PLoS neglected tropical diseases · 2024Article
- Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy.Frontiers in immunology · 2024Article
- Overexpression of AMPKγ2 increases AMPK signaling to augment human T cell metabolism and function.The Journal of biological chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Michelle H NelsonDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-7597-0923
Hannah M KnochelmannDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-0644-123X
Stefanie R BaileyDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Logan W HuffDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Jacob S BowersDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-2589-2351
Kinga Majchrzak-KuligowskaDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Megan M WyattDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Mark P RubinsteinDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-4748-0286
Shikhar MehrotraDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Michael I NishimuraDepartment of Surgery, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Kent E ArmesonDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-3758-6693
Paul G GiresiEpinomics, Menlo Park, CA, USA.
Michael J ZillioxDepartment of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.ORCID 0000-0001-7381-8397
Hal E BroxmeyerDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
Chrystal M PaulosDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. paulos@musc.edu paulos@emory.edu.ORCID 0000-0002-0784-2601
Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7MT-COHR: Training in Craniofacial and Oral Health ResearchT32DE017551 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YAO, HAI · 2006 to 2025
$10.3MSouth Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4MTRAINING PROGRAM FOR MEDICAL SCIENTISTST32GM008716 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DEMORE, NANCY · 1999 to 2024
$9.3MLymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responsesR01CA222817 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUBINSTEIN, MARK P, WRANGLE, JOHN M. · 2019 to 2023
$2.0MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MResearch Specialist Support of a Well-Established Cancer Immunotherapy Research Program Focused on Improving Adoptive T Cell Therapy (ACT)R50CA233168 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WYATT, MEGAN M · 2018 to 2022
$532kThe role of DCLK1 in the initiation of pancreatic ductal adenocarcinoma and colorectal cancerR50CA233186 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI QU, DONGFENG · 2018 to 2022
$448kDefining and translating the properties that sustain the antitumor efficacy of Th17 cellsF30CA200272 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BOWERS, JACOB S · 2015 to 2018
$182kDetermining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transferF30CA243307 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KNOCHELMANN, HANNAH MARIE · 2019 to 2022
$164kElucidating the role of CD26 in T cell-mediated tumor immunityF31CA192787 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BAILEY, STEFANIE · 2015 to 2017
$131kNCATS NIH HHS UL1 TR000062NCI NIH HHS F30 CA200272NCI NIH HHS F30 CA243307NCI NIH HHS F31 CA192787NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA208514NCI NIH HHS R01 CA222817NCI NIH HHS R50 CA233168NCI NIH HHS R50 CA233186NIDCR NIH HHS T32 DE017551NIGMS NIH HHS T32 GM008716
Abstract
How naturally arising human CD4
Indexed as
NeoplasmsReceptors, Chimeric AntigenCD4-Positive T-LymphocytesDipeptidyl Peptidase 4HumansT-LymphocytesDipeptidyl Peptidase 4Receptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.